BioSpace News Archive

The findings also highlight additional mechanistic, drug product stability, pharmacokinetics and toxicology studies that support the candidate as a potential HIV prevention and treatment.

Onward Therapeutics and Institut du Cancer de Montpellier announced the execution of an exclusive collaboration and worldwide option and license agreement based on a research program in onco-metabolism being conducted by ICM, Montpellier, France.

THR-149 is a potent plasma kallikrein inhibitor for the treatment of DME in the roughly 40% of the patient population respondingsuboptimally to anti-VEGF therapy

Polyphor AG announced that it will host a key opinion leader roundtable on Covid-19, the need for novel therapies for severe infections and the potential role of balixafortide, a selective CXCR4 antagonist, on Thursday, June 10, 2021 at 8am Eastern Time/2pm Central European Time.

Astellas Pharma Inc. announced the presentation of new data in acute myeloid leukemia at the European Hematology Association virtual congress, taking place June 9-17.

BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that the U.S. Food and Drug Administration has granted Fast Track designation for Bemcentinib in combination with an anti-PD-1 agent for the treatment of patients with AXL-positive advanced/metastatic non-small cell lung cancer.

AB Science SA is providing a summary of the live webcast held on June 3, 2021 following the voluntary hold in the clinical studies of masitinib.

According to the report, the global vascular closure devices market was valued at US$ 0.8 Bn in 2018 and is projected to expand at a CAGR of ~7% from 2019 to 2027.

According to the report, the global polypill products market was valued at US$ 29.7 Bn in 2018 and is projected to expand at a CAGR of ~2% from 2019 to 2027.

According to the report, the global recombinant factor C assay market was valued at ~US$ 13 Mn in 2018 and is projected to expand at a considerable CAGR during the forecast period.